Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Top German court to rule on claims by Wirecard shareholders - 2Treason trial of South Sudan's suspended VP is further eroding peace deal, UN experts say
- 3Desired Travel Objections Worldwide: Where to Go Straightaway
- 4Israeli girl suffers cardiac arrest during sirens in Safed, hospitalized in serious condition
- 5Visiting This Japanese City Just Got A Little More Expensive (Here's What Travelers Should Know)
- Grasping the Qualifications Among Separation and Dissolution
- Investigating Cooking and Culinary Expressions: An Excursion Through Flavors
- The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- Benihana is 60 years old. Gen Z is lining up.
- Claim that Israel opened 'sewage dam' into Gaza's main river undersells sanitation crisis
- Craig the beer-ambassador elephant dies aged 54
- Lily Allen 2026 'West End Girl' arena tour: How to get tickets, prices and more
- Artemis 2 astronauts — now halfway to the moon — report 'burning smell' from toilet, but everything's fine
- The Way to Monetary Freedom: A Viable Aide
